Cellectar Biosciences, Inc.
CLRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $26 | $27 | $19 | $18 |
| G&A Expenses | $26 | $12 | $10 | $7 |
| SG&A Expenses | $26 | $12 | $10 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52 | $39 | $29 | $24 |
| Operating Income | -$52 | -$39 | -$29 | -$24 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7 | -$4 | -$3 | $0 |
| Pre-Tax Income | -$45 | -$43 | -$32 | -$24 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$45 | -$43 | -$32 | -$24 |
| % Margin | – | – | – | – |
| EPS | -36.52 | -104.988 | -135.179 | -130.353 |
| % Growth | 65.2% | 22.3% | -3.7% | – |
| EPS Diluted | -41.89 | -104.988 | -135.179 | -130.353 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$51 | -$39 | -$29 | -$24 |
| % Margin | – | – | – | – |